Executive Summary
Compass Pathways plc, a mental health care company pioneering psilocybin therapy, recently announced positive results from its Phase 3 clinical trial evaluating COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD). The trial demonstrated statistically significant improvements in depressive symptoms compared to placebo, marking a critical